KANO
LIVE

Serial Number

97700230

Owner

Kano Therapeutics Inc.

Attorney

Rocky Cislak

Filing Date

Dec 1, 2022

Add to watchlist:

No watchlists yet
View on USPTO

KANO Trademark

Serial Number: 97700230

KANO is a trademark filed by Kano Therapeutics Inc. on December 1, 2022. The trademark is classified under Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

Kano Therapeutics Inc. (3 trademarks)

700 Main Street
Cambridge, MA 02139

Entity Type: 03

Trademark Details

Filing Date

December 1, 2022

Registration Date

Not Registered

Published for Opposition

January 23, 2024

Goods & Services

Pharmaceutical preparations for single-stranded DNA; Biologics, namely, nucleic acids for use as therapeutics for clinical and medical use

Custom manufacturing of nucleic acids for diagnostic, medical and commercial applications in relation to cell and gene therapies; Custom manufacturing of nucleic acids, biological organisms and components and products thereof in the nature of therapeutics for pharmaceutical drug development; Manufacturing services for others, namely, manufacture of synthetic DNA and genes; Custom manufacturing, namely, synthesis of pharmaceuticals

Pharmaceutical drug development services; Scientific research and development of synthesis of pharmaceuticals; Scientific research and development; Pharmaceutical, medical, scientific, and biopharmaceutical research and development; Biochemical research and development services, namely, custom development and synthesis of nucleic acids, biological organisms, and components and products thereof for pharmaceutical drug development; Design and development in the field of custom synthesis of cells and vectors for diagnostic, medical and commercial applications in relation to the design of nucleic acids and genetic medicines; Bioinformatic design of genetically engineered organisms; Research, design, and development of genetically engineered organisms; Product development consultation in the fields of pharmaceutical, medical, scientific, and biopharmaceutical research and development; Product development in the fields of products for pharmaceutical drug development; Research and development in the field of pharmaceuticals; Research and design services relating to pharmaceuticals; Research in the field of pharmaceutical preparations

Filing History

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 13, 2026 EXRA
SOU EXTENSION 4 GRANTED
Mar 12, 2026 EX4G
SOU EXTENSION 4 FILED
Mar 12, 2026 EXT4
SOU TEAS EXTENSION RECEIVED
Mar 12, 2026 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Sep 16, 2025 EXRA
SOU EXTENSION 3 GRANTED
Sep 15, 2025 EX3G
SOU EXTENSION 3 FILED
Sep 15, 2025 EXT3
SOU TEAS EXTENSION RECEIVED
Sep 15, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 20, 2025 EXRA
SOU EXTENSION 2 GRANTED
Mar 19, 2025 EX2G
SOU EXTENSION 2 FILED
Mar 19, 2025 EXT2
SOU TEAS EXTENSION RECEIVED
Mar 19, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Sep 16, 2024 EXRA
SOU EXTENSION 1 GRANTED
Sep 16, 2024 EX1G
SOU EXTENSION 1 FILED
Sep 16, 2024 EXT1
SOU TEAS EXTENSION RECEIVED
Sep 16, 2024 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Mar 19, 2024 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jan 23, 2024 NPUB
PUBLISHED FOR OPPOSITION
Jan 23, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jan 3, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Dec 14, 2023 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 13, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 12, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 12, 2023 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Sep 13, 2023 GNRN
NON-FINAL ACTION E-MAILED
Sep 13, 2023 GNRT
NON-FINAL ACTION WRITTEN
Sep 13, 2023 CNRT
ASSIGNED TO EXAMINER
Sep 11, 2023 DOCK
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Mar 22, 2023 TCCA
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Mar 22, 2023 EWAF
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Mar 22, 2023 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Mar 22, 2023 REAP
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Dec 28, 2022 NWOS
NEW APPLICATION ENTERED
Dec 5, 2022 NWAP